Novel treatment (new drug/intervention; established drug/procedure in new situation)
Successful repeated treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP
1 Clinical Neurophysiology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden
2 Haematology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden
3 Neurology, Uppsala University Hospital, Uppsala, SE-751 85, Sweden
Correspondence to:
hans.axelson{at}akademiska.se
Chronic inflammatory demyelinating polyneuropathy (CIDP) is characterised by the occurrence of symmetrical weakness and sensory impairment in arms and legs. The course is relapsing or chronic and progressing. CIDP is considered to be an autoimmune disease, which is supported by the beneficial response to immunomodulating therapies in most patients. We report on a patient with CIDP who has been in remission for more than 3 years after treatment with high dose cyclophosphamide and autologous blood stem cell transplantation in CIDP on two occasions.
Register for free content
The full text of all Editor's Choice articles and summaries of every article are free without registration
The full text of Images in ... articles are free to registered users
Only fellows can access the full text of case reports (apart from Editor's Choice) - become a fellow today, or encourage your institution to, so that together we can grow and develop this resource
Don't forget to sign up for content alerts so you keep up to date with all the case reports as they are published, and let us know what you think by commenting on the Editor's blog
